InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,230.00
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,144.85
(
0.09%
)
Post# of 252300
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JJM760 post# 151255

Thursday, 10/25/2012 9:35:43 PM

Thursday, October 25, 2012 9:35:43 PM

Post# of 252300
ARIA/NVS/BMY—The possibility of some patients being able to stop TKI treatment (specifically Tasigna) without incurring a relapse was mentioned on NVS’ 2Q12 CC (#msg-77720983). It’s a pretty big deal for the CML market if this idea pans out in clinical trials; as an ARIA investor, you should be hoping it doesn’t.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up